X

Drug Profile

Iguratimod - Simcere

Alternative Names: Iremod

Latest Information Update: 02 Oct 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Simcere Pharmaceutical Group
Class Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Benzopyrans; Chromones; Small molecules; Sulfonamides
Mechanism of Action Cyclo-oxygenase 2 inhibitors; Cytokine inhibitors; Tumour necrosis factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Rheumatoid arthritis
Phase II Sjogren's syndrome

Most Recent Events

22 Mar 2021 Phase-II clinical trials in Sjogren's syndrome in China (PO) (NCT04830644)
30 Sep 2020 Simcere Pharmaceutical Group received IND approval from The National Medical Products Administration (NMPA) for in Sjögren’s syndrome in September 2020
06 Feb 2019 Chemical structure information added

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com